BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32891647)

  • 1. Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer.
    Hiraoka N; Nitta H; Ohba A; Yoshida H; Morizane C; Okusaka T; Nara S; Esaki M; Kishi Y; Shimada K
    Hum Pathol; 2020 Nov; 105():9-19. PubMed ID: 32891647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.
    Pignochino Y; Sarotto I; Peraldo-Neia C; Penachioni JY; Cavalloni G; Migliardi G; Casorzo L; Chiorino G; Risio M; Bardelli A; Aglietta M; Leone F
    BMC Cancer; 2010 Nov; 10():631. PubMed ID: 21087480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 gene (ERBB2) amplification is a low-frequency driver with potential predictive value in gallbladder carcinoma.
    Albrecht T; Rausch M; Roessler S; Geissler V; Albrecht M; Halske C; Seifert C; Renner M; Singer S; Mehrabi A; Vogel MN; Pathil-Warth A; Busch E; Köhler B; Rupp C; Weiss KH; Springfeld C; Röcken C; Schirmacher P; Goeppert B
    Virchows Arch; 2020 Jun; 476(6):871-880. PubMed ID: 31838585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?
    Galdy S; Lamarca A; McNamara MG; Hubner RA; Cella CA; Fazio N; Valle JW
    Cancer Metastasis Rev; 2017 Mar; 36(1):141-157. PubMed ID: 27981460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status.
    Yoshida H; Shimada K; Kosuge T; Hiraoka N
    Virchows Arch; 2016 Apr; 468(4):431-9. PubMed ID: 26758058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testing for ROS1, ALK, MET, and HER2 rearrangements and amplifications in a large series of biliary tract adenocarcinomas.
    Augustin J; Gabignon C; Scriva A; Menu L; Calmel C; Scatton O; Paye F; Fléjou JF; Praz F; Cervera P; Wendum D
    Virchows Arch; 2020 Jul; 477(1):33-45. PubMed ID: 32447492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
    Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
    Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugate.
    Yamashita-Kashima Y; Yoshimura Y; Fujimura T; Shu S; Yanagisawa M; Yorozu K; Furugaki K; Higuchi R; Shoda J; Harada N
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):659-671. PubMed ID: 30659304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel gene-protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity.
    Nishida Y; Kuwata T; Nitta H; Dennis E; Aizawa M; Kinoshita T; Ohtsu A; Ochiai A
    Gastric Cancer; 2015 Jul; 18(3):458-66. PubMed ID: 24917219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The epidemiological trends of biliary tract cancers in the United States of America.
    Jiang Y; Jiang L; Li F; Li Q; Yuan S; Huang S; Fu Y; Yan X; Chen J; Li H; Li S; Liu J
    BMC Gastroenterol; 2022 Dec; 22(1):546. PubMed ID: 36581813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR and HER2 expression in advanced biliary tract cancer.
    Harder J; Waiz O; Otto F; Geissler M; Olschewski M; Weinhold B; Blum HE; Schmitt-Graeff A; Opitz OG
    World J Gastroenterol; 2009 Sep; 15(36):4511-7. PubMed ID: 19777609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers.
    Nakazawa K; Dobashi Y; Suzuki S; Fujii H; Takeda Y; Ooi A
    J Pathol; 2005 Jul; 206(3):356-65. PubMed ID: 15892172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization.
    Kanayama K; Imai H; Yoneda M; Hirokawa YS; Shiraishi T
    Cancer Sci; 2016 Apr; 107(4):536-42. PubMed ID: 26752196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum HER2 levels and HER2 status in tumor cells in advanced gastric cancer patients.
    Sasaki T; Fuse N; Kuwata T; Nomura S; Kaneko K; Doi T; Yoshino T; Asano H; Ochiai A; Komatsu Y; Sakamoto N; Ohtsu A
    Jpn J Clin Oncol; 2015 Jan; 45(1):43-8. PubMed ID: 25378649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updated UK Recommendations for HER2 assessment in breast cancer.
    Rakha EA; Pinder SE; Bartlett JM; Ibrahim M; Starczynski J; Carder PJ; Provenzano E; Hanby A; Hales S; Lee AH; Ellis IO;
    J Clin Pathol; 2015 Feb; 68(2):93-9. PubMed ID: 25488926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer.
    Vivaldi C; Fornaro L; Ugolini C; Niccoli C; Musettini G; Pecora I; Cacciato Insilla A; Salani F; Pasquini G; Catanese S; Lencioni M; Masi G; Campani D; Fontantini G; Falcone A; Vasile E
    Oncologist; 2020 Oct; 25(10):886-893. PubMed ID: 32353192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.
    Plum PS; Gebauer F; Krämer M; Alakus H; Berlth F; Chon SH; Schiffmann L; Zander T; Büttner R; Hölscher AH; Bruns CJ; Quaas A; Loeser H
    BMC Cancer; 2019 Jan; 19(1):38. PubMed ID: 30621632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas.
    Nassar A; Khoor A; Radhakrishnan R; Radhakrishnan A; Cohen C
    Int J Clin Exp Pathol; 2014; 7(9):6254-61. PubMed ID: 25337277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features.
    Park JS; Yoon G; Kim HJ; Park SY; Choi GS; Kang MK; Kim JG; Jang JS; Seo AN
    Virchows Arch; 2018 Oct; 473(4):413-423. PubMed ID: 30056472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 is frequently overexpressed in hepatoid adenocarcinoma and gastric carcinoma with enteroblastic differentiation: a comparison of 35 cases to 334 gastric carcinomas of other histological types.
    Fujimoto M; Matsuzaki I; Nishino M; Iwahashi Y; Warigaya K; Kojima F; Ono K; Murata SI
    J Clin Pathol; 2018 Jul; 71(7):600-607. PubMed ID: 29305518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.